Here is the AZ part of the story about George Soros dumping ALL of his AZ stock. Where is Pfizer now with their $120 billion offer…nowhere to be found because of Frenchie!
AstraZeneca's turnaround story hinges on a high-risk strategy
Like most big pharmas, AstraZeneca has gotten walloped by the ongoing patent cliff. Specifically, the loss of exclusivity on its top-selling acid reflux drug, Nexium, caused revenue to crater by nearly 30% in the fourth quarter compared with a year ago. Making matters worse, its megablockbuster cholesterol drug, Crestor, is set to lose patent protection in the U.S. in 2016.
Source: AstraZeneca.
Management has thus looked toward the promising field of immuno-oncology to help reverse this trend. To do so, it has built one of the most comprehensive and integrative immunotherapy programs in the business.
AstraZeneca's early stage immuno-oncology platform centers on three therapeutic target areas: antigen presentation, T-cell killing, and the tumor's micro-environment. The company is also conducting numerous clinical trials employing a combination of immunotherapies, with the goal of hitting multiple therapeutic targets at once.
While AstraZeneca believes it can boost sales by a staggering 70% by 2017, you should bear in mind that a large chunk of this forward-looking revenue estimate is based on immunotherapy products that are still in the early stages of clinical testing. As there is no guarantee they will prove to be effective -- or even safe, for that matter -- AstraZeneca's huge bet on immuno-oncology is a risky proposition to say the least, which is probably why Soros dumped the stock completely in the fourth quarter.
AstraZeneca's turnaround story hinges on a high-risk strategy
Like most big pharmas, AstraZeneca has gotten walloped by the ongoing patent cliff. Specifically, the loss of exclusivity on its top-selling acid reflux drug, Nexium, caused revenue to crater by nearly 30% in the fourth quarter compared with a year ago. Making matters worse, its megablockbuster cholesterol drug, Crestor, is set to lose patent protection in the U.S. in 2016.
Source: AstraZeneca.
Management has thus looked toward the promising field of immuno-oncology to help reverse this trend. To do so, it has built one of the most comprehensive and integrative immunotherapy programs in the business.
AstraZeneca's early stage immuno-oncology platform centers on three therapeutic target areas: antigen presentation, T-cell killing, and the tumor's micro-environment. The company is also conducting numerous clinical trials employing a combination of immunotherapies, with the goal of hitting multiple therapeutic targets at once.
While AstraZeneca believes it can boost sales by a staggering 70% by 2017, you should bear in mind that a large chunk of this forward-looking revenue estimate is based on immunotherapy products that are still in the early stages of clinical testing. As there is no guarantee they will prove to be effective -- or even safe, for that matter -- AstraZeneca's huge bet on immuno-oncology is a risky proposition to say the least, which is probably why Soros dumped the stock completely in the fourth quarter.
SOROS DUMPS ALL OF HIS AZ STOCK!
Aucun commentaire:
Enregistrer un commentaire